Higher adherence with 3‐year entecavir treatment than lamivudine or telbivudine in treatment‐naïve Taiwanese patients with chronic hepatitis B

Oral nucleos(t)ide analogs (NAs) are effective in suppressing hepatitis B virus (HBV) replication in treatment naïve chronic hepatitis B (CHB) patients. However, little is known about the treatment modification and adherence on such patients with prolonged NA treatment.

[1]  O. Yokosuka,et al.  Adherence to Medication Is a More Important Contributor to Viral Breakthrough in Chronic Hepatitis B Patients Treated with Entecavir Than in Those with Lamivudine , 2013, International journal of medical sciences.

[2]  Jia-Horng Kao,et al.  Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update , 2012, Hepatology International.

[3]  J. Kao,et al.  Recent advances in the treatment of chronic hepatitis B , 2011, Expert opinion on pharmacotherapy.

[4]  B. McMahon,et al.  Chronic hepatitis B: Update 2009 , 2009, Hepatology.

[5]  M. Manns,et al.  Trial Results : Telbivudine Is Superior to Lamivudine in atients With Chronic Hepatitis B UN – , 2022 .

[6]  A. Lok,et al.  Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. , 2007, Gastroenterology.

[7]  Ching-Lung Lai,et al.  Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. , 2006, The New England journal of medicine.

[8]  J. Kao.  Hepatitis B Virus Genotypes and Hepatocellular Carcinoma in Taiwan , 2003, Intervirology.

[9]  Ding-Shinn Chen,et al.  Global control of hepatitis B virus infection. , 2002, The Lancet. Infectious diseases.

[10]  Y. Liaw,et al.  Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 2000, Gastroenterology.

[11]  E. Schiff,et al.  Lamivudine as initial treatment for chronic hepatitis B in the United States. , 1999, The New England journal of medicine.

[12]  N. Leung,et al.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 1998, The New England journal of medicine.

[13]  Ding‐Shinn Chen,et al.  Hepatitis B Virus Infection , 2007 .

[14]  Ding‐Shinn Chen,et al.  From hepatitis to hepatoma: lessons from type B viral hepatitis. , 1993, Science.

[15]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .

[16]  EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. , 2012, Journal of hepatology.

[17]  A. Lok,et al.  Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. , 2011, Journal of hepatology.

[18]  Norman Gitlin,et al.  Chronic hepatitis B : an update , 2010 .

[19]  D. Snydman.  Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis BLai C-L, for the BEHoLD AI463027 Study Group (Queen Mary Hosp, Hong Kong; et al) N Engl J Med 354:1011–1020, 2006§ , 2007 .

[20]  Ally,et al.  A ONE-YEAR TRIAL OF LAMIVUDINE FOR CHRONIC HEPATITIS B , 2000 .